1. Council for International Organizations of Medical Sciences (CIOMS). Benefit-risk balance for marketed drugs: evaluating safety signals. Report of CIOMS Working Group IV, http://www.cioms.ch/publications/g4-benefit-risk.pdf. (accessed October 12, 2012)
2. Guidance for industry: premarketing risk assessment,2005
3. European Medicine Agency (EMEA) CHMP. Benefit-risk methodology project: Work Package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment. 2010; http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000314.jsp&mid=WC0b01ac0580223ed6#section2 (accessed October 22, 2012)
4. FDA. Draft guidance for industry and Food and Drug Administration Staff: the 510(k) program: evaluating substantial equivalence in premarket notifications [510(k)]. 2011; http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM284443.pdf (accessed October 26, 2012)
5. Economic evaluation for devices and drugs—same or different?;Drummond;Value Health,2009